Incysus Therapeutics to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2019

New York, New York, UNITED STATES

NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Lawrence S. Lamb, Ph.D., scientific co-founder and Chief Scientific Officer of Incysus will present new preclinical data on Incysus’ drug resistant immunotherapy (DRI) approach during the American Association for Cancer Research (AACR) Annual Meeting being held at the Georgia World Congress Center in Atlanta, Georgia from March 29 – April 3, 2019.

Poster Title:   Chemotherapy, checkpoint inhibition, and MGMT-modified adoptive gamma-delta (γδ) T cell-based therapy to treat post-resection, primary glioblastomas
Session Title:   Combination Immunotherapies I
Date and Time:    Monday, April 1, 2019, 1:00 – 5:00 p.m. EDT
Location:   Georgia World Congress Center, Exhibit Hall B, Poster Section 19
Presenter:   Lawrence S. Lamb, Ph.D.
Abstract (2262):    Recent evidence supports the crucial contribution of innate immunity to chemotherapy-based cancer treatments. Our previous in vitro modeling shows improved killing of glioblastoma (GBM) cell lines when γδ T cells are combined with alkylating agents such as Temozolomide (TMZ), which cause DNA damage but are also lymphodepleting. We now report findings from combined TMZ therapy with MGMT-modified γδ T cells (Drug Resistant Immunotherapy - DRI) in a xenograft (PDXT) mouse model of primary and recurrent GBM.

“The AACR Annual Meeting is an important event for Incysus this year and we are excited to present new data related to our DRI approach,” said William Ho, President and Chief Executive Officer of Incysus.  “Presentation of these data follows Dr. Lamb’s participation today in a scientific symposium at the Innate Killer Summit being held in San Diego.  That presentation, which will begin at 9:00am PDT at the Hilton San Diego Gaslamp Quarter, entitled, Unique advantages of γδ T cells for adoptive immunotherapy, is part of a session highlighting recent successes of γδ T cell-based therapy.”

About American Association for Cancer Research (AACR)
The American Association for Cancer Research (AACR) ( is a 501(c)(3) public charity headquartered in Philadelphia, PA. The mission of the AACR is to prevent and cure cancer through research, education, communication and collaboration. Through its programs and services, the AACR fosters cancer research and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer causes, prevention, diagnosis and treatment throughout the world.

About Innate Killer Summit 2019
The Innate Killer Summit is the leading, dedicated end-to-end meeting accelerating to market genetically engineered, off-the-shelf and cost-effective NK cell immunotherapies for solid tumor indications.  This year’s Summit will bring together over 100 of the field’s leading minds to share experience and knowledge on the optimal NK cell source and improve the efficacy of NK cell therapies through enhanced targeting methods.

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has filed two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages, including a checkpoint combination program.  The Company’s first program is targeted to leukemia and lymphoma patients and the IND related to this program was accepted by the FDA in late 2017.  The Company’s second program is targeted to treat patients with newly-diagnosed glioblastoma (GBM).  In collaboration with the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials during 2019.  For more information, visit

Incysus Therapeutics, Inc.
+1 646.600.6GDT